No Result

View All Result

No products in the cart.

Home Tag follicular lymphoma

Tag: follicular lymphoma

No clinical benefit of specific immunotherapy seen in lymphoma

Prolonged rituximab maintenance therapy does not provide overall survival benefit in low-burden follicular lymphoma

byVanessa Giulianoand1 others

January 28, 2024

1. In patients with low tumor burden follicular lymphoma (LTBFL): Rituximab maintenance therapy does not improve overall survival in comparison ...

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

byTeddy Guo

October 19, 2022

Click to read this study in the Journal of Clinical Oncology.

#VisualAbstract Oral azacitidine (CC-486) plus R-CHOP shows an acceptable safety profile in untreated diffuse large B-cell lymphoma

byKathleen Lau

March 3, 2022

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

byKathleen Lau

December 31, 2021

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

byJessie Willisand1 others

December 2, 2021

1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...

$#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma$

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

byKathleen Lau

December 2, 2021

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

byKathleen Lau

November 12, 2021

$#VisualAbstract Obinutuzumab-atezolizumab-lenalidomide is effective and tolerable in patients with relapsed/refractory follicular lymphoma$

#VisualAbstract Obinutuzumab-atezolizumab-lenalidomide is effective and tolerable in patients with relapsed/refractory follicular lymphoma

byKathleen Lau

September 3, 2021

#VisualAbstract Patients with follicular lymphoma experience a plateau in therapy initiation rates during their first decade of observation after diagnosis

byKathleen Lau

July 30, 2021

$#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma$

#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma

byKathleen Lau

December 11, 2020

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

Tag: follicular lymphoma

Prolonged rituximab maintenance therapy does not provide overall survival benefit in low-burden follicular lymphoma

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

#VisualAbstract Oral azacitidine (CC-486) plus R-CHOP shows an acceptable safety profile in untreated diffuse large B-cell lymphoma

#VisualAbstract Obinutuzumab plus lenalidomide is an active and safe therapy in advanced, previously untreated follicular lymphoma

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

#VisualAbstract Obinutuzumab-atezolizumab-lenalidomide is effective and tolerable in patients with relapsed/refractory follicular lymphoma

#VisualAbstract Patients with follicular lymphoma experience a plateau in therapy initiation rates during their first decade of observation after diagnosis

#VisualAbstract CONTRALTO Phase II: Venetoclax-Rituximab With or Without Bendamustine VS Bendamustine-Rituximab in Relapsed/Refractory Follicular Lymphoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports